Counterpoint: Intensive Glucose Control and Mortality in ACCORD—Still Looking for Clues
Year: 2010
Type: article
Abstract: Early cessation of the intensive glycemic treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial because of a 22% excess of all-cause mortality compared with the standard arm (1) came as an unpleasant surprise to many observers. Since then, considerable discussion of the significance of this result has ensued along with various theories as to why it occurred. In the companion article, a respected statistician, John Lachin, proposes yet another hypothesis: that the finding was due to the play of chance (2). In response, this article will address three
Source: Diabetes Care
DOI: 10.2337/dc10-1658
Author: Matthew C. Riddle
Institution: Oregon Health & Science University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2105229683
